For your practice
Compounded medication sourcing for hormone clinics
A hormone clinic hits two constraints the other practice types largely do not. Where a preparation is a controlled substance, holding it on site can trigger a state registration tied to that physical location — New Jersey’s prescribe-only exemption ends by its own terms once drugs are in the office. And the federal “essentially a copy” rule bites hardest where an approved product already exists at the same strength and route, which describes much of this category.
What makes a hormone clinic different?
Two things, and they pull in different directions.
The first is that a meaningful share of this category is scheduled. Once a preparation is a controlled substance, a second licensing regime switches on that has nothing to do with compounding rules, and it attaches to buildings rather than to companies. The second is that the federal restriction on compounding a copy of a commercially available drug applies most forcefully where an approved product already exists in the same strength and by the same route — which is the ordinary situation here, and much less common in categories built around preparations with no approved counterpart.
Neither constraint is visible in a conversation about which pharmacy to use. Both decide whether the arrangement works.
What changes the moment scheduled stock is on site?
The licence you thought you did not need.
New Jersey is the clearest illustration because its exemption ends in its own text. A practitioner who only prescribes is exempt from a state controlled-substance registration, and N.J.A.C. 13:45H-1.3 withdraws that exemption once controlled substances are contained in the office. The result is a registration tied to each physical location, not to the practice as a whole — so a second site is a second application, and the trigger is possession rather than volume.
Louisiana reaches a similar place by a different road. Its Board of Pharmacy issues a controlled-substance licence to facilities, and the category expressly covers registered outsourcing facilities as well as distributors, which means the supplier’s own credential and yours are separate questions that both have to be answered before scheduled product ships.
Can you send a patient home with it?
In one of the states we have read, if the item is scheduled, generally not — and this is the trap most likely to catch a practice that already dispenses non-scheduled preparations without difficulty.
Florida’s § 465.0276(1)(b) provides that a practitioner registered under that section "may not dispense a controlled substance listed in Schedule II or Schedule III," subject to a short list of exceptions covering samples, corrections settings, a limited supply incident to a surgical procedure, approved trials, methadone and certain facilities. Administering a scheduled compounded preparation in the office is a different act and is not caught by it: § 465.003(13) settles the threshold with "The administration shall not be considered dispensing."
Florida also has no separate state controlled-substance registration for practitioners — § 893.02 builds the federal registration into the definition of "practitioner" — so the state’s constraint here is on the act, not on an extra credential.
What does the copy rule do to your menu?
It decides which preparations a state-licensed 503A pharmacy may compound for your patients at all, and it turns on facts about the approved product rather than on your state.
FDA’s current statement of the test asks two things about the approved product. Does a commercially available drug product contain the same active pharmaceutical ingredient, at a strength that is the same, similar or easily substitutable; and can that commercially available product be used by the route of administration prescribed for the compounded one. Where both hold, the compounded product is treated as essentially a copy — unless the prescriber determines and documents that it contains a change producing a significant difference for an identified individual patient.
That documentation requirement is prescriber work, not pharmacy work, and it is per patient. The full doctrine, including what FDA has said about combination products and about frequency, is set out at essentially a copy of a commercially available drug.
Does your state permit office stock at all?
Separately from everything above, and the answers are not alike.
Georgia’s rule prohibits non-patient-specific distribution for office use by a practitioner other than a veterinarian, in those words, while expressly leaving outsourcing facilities untouched. Illinois permits office use for non-sterile preparations and prohibits it for sterile ones unless the supplier is registered as an outsourcing facility and licensed as an Illinois wholesale drug distributor. California’s § 4059.5(d) lets a physician’s own office be furnished dangerous drugs without a board licence, while clinic settings defined by statute need one.
Each state’s rule text, citation and last-reviewed date is in the state-by-state office-use guide, and the ordering sequence itself is set out at how to place an office-use order. Practices whose menu is decided mainly by the copy rule rather than by a state rule should also read the page written for weight-management clinics, and a practice seeing patients across state lines has a further set of per-state questions, covered for telehealth companies.
What to bring when you apply
Four answers, and the first two are the ones that usually stall an application.
Which items are scheduled, because that decides whether a location-level registration attaches before anything ships. Every physical location that will hold stock, since the registrations that matter here attach per site. Whether each item is administered in the office or dispensed to the patient, item by item rather than as a general policy. And which prescriber signs, with the state of licensure, because the copy-rule documentation is theirs to make and record.
If you want those mapped against your state and your list before committing, you can apply for an account.